Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 5/20 | 0.40 |
| ▸ | ACHE | P22303 | 3/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | CRHBP | P24387 | 1/20 | 0.33 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6343469 | 1.00 | KCNH2 (0.40) | KCNH2ACHESLC6A4ALDH1A1ADRB3 | |
| SCHEMBL6391154 | 0.89 | ADRB3 (0.39) | KCNH2ALDH1A1ADRB3MAPT | |
| SCHEMBL6337763 | 0.83 | SSTR4 (0.41) | ADRB3 | |
| SCHEMBL21278553 | 0.77 | ADRB3 (0.39) | ADRB3MAPT | |
| SCHEMBL16682352 | 0.76 | KCNH2 (0.60) | KCNH2ACHESLC6A4MAPTCRHBP | |
| SCHEMBL6335185 | 0.75 | ADRB3 (0.42) | ADRB3MAPT | |
| SCHEMBL6181736 | 0.73 | KCNH2 (0.57) | KCNH2ACHESLC6A4ALDH1A1MAPT | |
| SCHEMBL6247395 | 0.72 | KCNH2 (0.56) | KCNH2MAPTCRHBPCRHR2 | |
| SCHEMBL12925089 | 0.72 | KCNH2 (0.55) | KCNH2ALDH1A1MAPTCRHBPCRHR2 | |
| SCHEMBL6404141 | 0.71 | ADRB3 (0.51) | ADRB3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6939867-B2 | Phenyl sulfamide derivatives as dietetics, antidiabetics, and hypotensive agents | PFIZER INC. (US) | 2005-09-06 | — | — | US | disclosed |
| US-20020128247-A1 | Beta3 agonists and uses thereof | DOW ROBERT L (US) | 2002-09-12 | — | — | US | disclosed |
| EP-1236723-A1 | Sulfamide derivatives useful as beta3 agonists and pharmaceutical uses thereof | Pfizer Products Inc. (US) | 2002-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128247-A1 | Beta3 agonists and uses thereof | ADRB3, ADRB1, ADRB2 | KCNH2 2353/4885ACHE 1756/4885SLC6A4 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.